The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers.
The post FDA Clears the First Digital Therapeutic for Depression, But Will Payers Cover It? appeared first on MedCity News.
